Risk Factors for Progression to Chronic Chagas Cardiomyopathy: A Systematic Review and Meta-Analysis
- PMID: 36848894
- PMCID: PMC10076993
- DOI: 10.4269/ajtmh.22-0630
Risk Factors for Progression to Chronic Chagas Cardiomyopathy: A Systematic Review and Meta-Analysis
Abstract
Approximately one-third of people with chronic Trypanosoma cruzi infection develop Chagas cardiomyopathy, which carries a poor prognosis. Accurate prediction of which individuals will go on to develop Chagas cardiomyopathy remains elusive. We performed a systematic review of literature comparing characteristics of individuals with chronic Chagas disease with or without evidence of cardiomyopathy. Studies were not excluded on the basis of language or publication date. Our review yielded a total of 311 relevant publications. We further examined the subset of 170 studies with data regarding individual age, sex, or parasite load. A meta-analysis of 106 eligible studies indicated that male sex was associated with having Chagas cardiomyopathy (Hedge's g: 1.56, 95% CI: 1.07-2.04), and a meta-analysis of 91 eligible studies indicated that older age was associated with having Chagas cardiomyopathy (Hedge's g: 0.66, 95% CI: 0.41-0.91). A meta-analysis of four eligible studies did not find an association between parasite load and disease state. This study provides the first systematic review to assess whether age, sex, and parasite load are associated with Chagas cardiomyopathy. Our findings suggest that older and male patients with Chagas disease are more likely to have cardiomyopathy, although we are unable to identify causal relationships due to the high heterogeneity and predominantly retrospective study designs in the current literature. Prospective, multidecade studies are needed to better characterize the clinical course of Chagas disease and identify risk factors for progression to Chagas cardiomyopathy.
Figures
Similar articles
-
Risk progression to chronic Chagas cardiomyopathy: influence of male sex and of parasitaemia detected by polymerase chain reaction.Heart. 2003 Oct;89(10):1186-90. doi: 10.1136/heart.89.10.1186. Heart. 2003. PMID: 12975414 Free PMC article.
-
Circulating Trypanosoma cruzi load and major cardiovascular outcomes in patients with chronic Chagas cardiomyopathy: a prospective cohort study.Trop Med Int Health. 2020 Dec;25(12):1534-1541. doi: 10.1111/tmi.13487. Epub 2020 Sep 29. Trop Med Int Health. 2020. PMID: 32910537
-
Risk of Chronic Cardiomyopathy Among Patients With the Acute Phase or Indeterminate Form of Chagas Disease: A Systematic Review and Meta-analysis.JAMA Netw Open. 2020 Aug 3;3(8):e2015072. doi: 10.1001/jamanetworkopen.2020.15072. JAMA Netw Open. 2020. PMID: 32865573 Free PMC article.
-
A systematic review and meta-analysis of mortality in chronic Chagas cardiomyopathy versus other cardiomyopathies: higher risk or fiction?Rev Esp Cardiol (Engl Ed). 2024 Oct;77(10):843-850. doi: 10.1016/j.rec.2024.02.014. Epub 2024 Mar 12. Rev Esp Cardiol (Engl Ed). 2024. PMID: 38485084 English, Spanish.
-
Interleukin 10 Polymorphisms as Risk Factors for Progression to Chagas Disease Cardiomyopathy: A Case-Control Study and Meta-Analysis.Front Immunol. 2022 Jul 4;13:946350. doi: 10.3389/fimmu.2022.946350. eCollection 2022. Front Immunol. 2022. PMID: 35860267 Free PMC article.
Cited by
-
Localized cardiac small molecule trajectories and persistent chemical sequelae in experimental Chagas disease.Nat Commun. 2023 Oct 25;14(1):6769. doi: 10.1038/s41467-023-42247-w. Nat Commun. 2023. PMID: 37880260 Free PMC article.
-
Exercise Training Reduces Inflammation and Fibrosis and Preserves Myocardial Function and Perfusion in a Model of Chronic Chagas Cardiomyopathy.Arq Bras Cardiol. 2024 Sep 9;121(8):e20230707. doi: 10.36660/abc.20230707. eCollection 2024. Arq Bras Cardiol. 2024. PMID: 39258653 Free PMC article. English, Portuguese.
-
Intermittent suppressive posaconazole therapy is ineffective at mitigating cardiac and digestive tract pathologies in an experimental model of chronic Chagas disease.Antimicrob Agents Chemother. 2025 Jun 4;69(6):e0178624. doi: 10.1128/aac.01786-24. Epub 2025 May 5. Antimicrob Agents Chemother. 2025. PMID: 40323434 Free PMC article.
-
Sexual dimorphism-driven differences are overcome in a preclinical vaccine model against Trypanosoma cruzi.Front Immunol. 2025 Jun 26;16:1526573. doi: 10.3389/fimmu.2025.1526573. eCollection 2025. Front Immunol. 2025. PMID: 40642088 Free PMC article.
-
Advances in the Understanding and Treatment of Chronic Chagas Cardiomyopathy.Cardiol Res. 2024 Oct;15(5):340-349. doi: 10.14740/cr1665. Epub 2024 Sep 16. Cardiol Res. 2024. PMID: 39420972 Free PMC article. Review.
References
-
- 2015. Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Wkly Epidemiol Rec 90: 33–43. - PubMed
-
- Pérez-Molina JA, Molina I, 2018. Chagas disease. Lancet 391: 82–94. - PubMed
-
- Bern C, Martin DL, Gilman RH, 2011. Acute and congenital Chagas disease. Adv Parasitol 75: 19–47. - PubMed
-
- Nunes MCP. et al., 2018. Chagas cardiomyopathy: an update of current clinical knowledge and management: a scientific statement from the American Heart Association. Circulation 138: e169–e209. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical